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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $530 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Calcitriol and 
doxercalciferol are 
equivalent in treating 
bone disease of CKD
Children with renal failure have seri-
ous bone disease due to secondary 
hyperparathyroidism despite treat-
ment with calcitriol. Wesseling-Perry 
et al. compared the effects of calcitriol 
and doxercalciferol on bone, mineral, 
and fibroblast growth factor-23 (FGF-
23) metabolism in a randomized trial 
of 60 children with secondary hyper-
parathyroidism on peritoneal dialysis, 
treated for 8 months with either oral 
calcitriol or doxercalciferol combined 
with either calcium carbonate or seve-
lamer. Bone formation rates decreased 
during therapy, and final values were 
within the normal range in most of the 
patients. Serum phosphate concentra-
tions were controlled equally well by 
both binders, but serum calcium lev-
els increased during treatment with 
calcium carbonate. Serum parathyroid 
hormone levels were decreased by 35% 
in all groups. Baseline plasma FGF-23 
values were significantly elevated and 
rose more than fourfold with calcitriol 
and doxercalciferol, irrespective of 
phosphate binder. Thus, doxercalciferol 
is as effective as calcitriol in control-
ling serum parathyroid hormone levels 
and suppressing the bone formation 
rate. The use of phosphate binders has 
Angiotensin II 
phosphorylates the 
thiazide-sensitive 
Na-Cl cotransporter
Both angiotensin II and aldosterone inde-
pendently increase NaCl absorption in the 
distal tubule. As they report in this issue, 
van der Lubbe et al. examined the mecha-
nism of this regulation by studying the 
expression of the thiazide-sensitive Na-Cl 
cotransporter (TSC) in the distal tubule. 
They found that both hormones increased 
the abundance of TSC in the apical 
membrane and reduced sodium excretion. 
Both hormones increased the phosphoryla-
tion of this transporter. To examine which 
serine/threonine kinase might induce this 
phosphory lation, they found that the abun-
dance of SPAK was increased whereas that 
of WNKs was not, implying that it was the 
SPAK kinase that was the regulator.  These 
results may explain, in part, the hormo-
nal control of renal sodium excretion and 
the patho physiology of several forms of 
hypertension. See page 66.
allowed the use of high-dose vitamin 
D hormones, whose safety will require 
longer-term studies. See page 112.
eGFR and ACR are 
excellent initial 
predictors of mortality
Recently, Foley et al. attempted to 
answer the question of whether kid-
ney function tests such as estimated 
glomerular filtration rate (eGFR) or 
albumin–creatinine ratio (ACR) are use-
ful predictors of health outcomes. They 
attempted to rank these factors using 
the Third National Health and Nutri-
tion Examination Survey (NHANES 
III) database, which includes the clas-
sic predictors—low-density lipoprotein 
(LDL), cholesterol, smoking, and so on. 
To generate threshold values for early 
mortality using eGFR and ACR, they 
identified the values that would give the 
maximum predictive power in this large 
population that was followed for a sig-
nificant amount of time. ACR and eGFR 
were excellent prognostic discrimina-
tors, and their power exceeded that of 
commonly advocated public-health 
screening measures, such as LDL cho-
lesterol and fasting blood glucose. Using 
complex statistical algorithms, these 
studies show that ACR and eGFR may 
be at least as efficient for survival-based 
clinical triage as most other classic risk 
factors. See page 99.
